Oct 2000 Hemispherx Biopharma, Inc. has secured a major position into the fast growing area of human genomics by a strategic alliance with Chronix Biomedical.
Genomic research focuses on studying the map of the normal human genome.
Chronix's technology is based in part on the detours or 'reshuffled genes' the human genome map may take when confronted with viruses or other toxic environmental exposures. In addition, Hemispherx will make available to Chronix its considerable CFS data bank to enable the alliance to isolate potentially unique human gene sequences particular to CFS, GWS and related chronic diseases. Hemispherx Biopharma, which is based in Philadelphia, is a pharmaceutical company engaged in the manufacture and global clinical development of new drug entities in the nucleic acid class for chronic viral diseases and disorders of the immune system including CFS, HIV and Hepatitis. No part of this publication may be redistributed in any form without prior permission. Terms and conditions for users .